Advertisement
Advertisement

Bayer initiates asundexian Phase III study program

By:
Reuters
Updated: Aug 28, 2022, 07:38 UTC

BERLIN (Reuters) - Germany's Bayer said on Sunday it was starting a Phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.

The historical headquarters of German pharmaceutical and chemical maker Bayer AG is pictured in Leverkusen

BERLIN (Reuters) – Germany’s Bayer said on Sunday it was starting a Phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.

The drug candidate is a potential new treatment for patients with atrial fibrillation and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, Bayer said.

Bayer’s best-selling stroke prevention pill Xarelto, in which partner Johnson & Johnson holds some rights, will lose patent protection around 2026.

(Writing by Paul Carrel, Editing by Miranda Murray)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Did you find this article useful?

Advertisement